Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Etelcalcetide in SHPT
NCT01785875Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2013
- Primary completion
- Jul 2015
- Modality
- Peptides, Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Started Jul 2013; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01785875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01785875.